TulmiSTAR-02: tulmimetostat with Daro or Abi for mHSPC - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer, CDZR123C12101
Principal Investigator
Jeffrey W. Shevach, MD, MSCE
Medical Oncologist
Protocol Number
IRB:
PRO00119024
NCT:
NCT07190300
Phase
Phase I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment